|
1
|
Zhu C, Sun L, Wei Y, Xu D, Zhou Y. Characteristics and survival prognosis of patients with pure squamous cell carcinoma of the gallbladder. ANZ J Surg 2020; 91:E91-E97. [PMID: 33236449 DOI: 10.1111/ans.16452] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Revised: 10/31/2020] [Accepted: 11/06/2020] [Indexed: 01/03/2023]
Abstract
BACKGROUND Pure squamous cell carcinoma (SCC) of the gallbladder is rare and often confused with the adenosquamous carcinoma (ASC) subtype in previous studies. The present study was attempted to differentiate SCC from ASC by resolving their characteristics and prognosis. METHODS The Surveillance, Epidemiology, and End Results database was queried for SCC and ASC of gallbladder cases from 1988 to 2015. Patients' clinicopathological characteristics and survival were analysed between the groups. RESULTS Of the 709 patients with primary gallbladder cancer included in this study, 249 (35.1%) had pure SCC and the remaining 460 (64.9%) had ASC. It was found that pure SCC was associated with a larger median tumour size (58.0 versus 41.0 mm, P < 0.001), while ASC presented with a worse histological grade (47.4% versus 37.8% for grades III-IV, P = 0.019) and more lymph node invasion (27.4% versus 18.9%, P = 0.041). The 3-year overall survival and disease-specific survival rates in pure SCC were lower than those in ASC (7.5% versus 11.5% for overall survival, P < 0.001; 6.2% versus 10.9% for disease-specific survival, P < 0.001). Multivariate analysis showed that early Surveillance, Epidemiology, and End Results historic stage, treatment with surgery and chemotherapy were significant favourable prognostic factors for pure SCC, while tumour size, late study period, treatment with surgery and radiotherapy were significant predictors for ASC. CONCLUSION There were significant differences in the clinicopathological characteristics and survival prognosis between pure SCC and ASC. Surgery combined with chemotherapy is the preferred treatment option for pure SCC.
Collapse
Affiliation(s)
- Chenglong Zhu
- Department of Hepatobiliary & Pancreatovascular Surgery, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China
| | - Lu Sun
- Department of Surgery, First affiliated Hospital of Xiamen University, Xiamen, China
| | - Youzhu Wei
- Department of Hepatobiliary & Pancreatovascular Surgery, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China
| | - Donghui Xu
- Department of Surgery, First affiliated Hospital of Xiamen University, Xiamen, China
| | - Yanming Zhou
- Department of Hepatobiliary & Pancreatovascular Surgery, Xiamen Humanity Hospital, Fujian Medical University, Xiamen, China.,Department of Surgery, First affiliated Hospital of Xiamen University, Xiamen, China
| |
Collapse
|
|
2
|
Ivashkin VT, Poluektova EA, Glazunov AB, Putilovskiy MA, Epstein OI. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC Gastroenterol 2019; 20:2. [PMID: 31892312 PMCID: PMC6938622 DOI: 10.1186/s12876-019-1143-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Accepted: 12/11/2019] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The aim of this study was to investigate the efficacy and safety of the novel complex drug, consisting of released-active form of antibodies to S-100 protein, tumor necrosis factor-α and histamine, (Kolofort) under outpatient conditions in patients with functional dyspepsia (FD), irritable bowel syndrome (IBS), and FD-IBS overlap. METHODS The subjects of the observational noninterventional retrospective program were the data of 14,362 outpatient records of patients with diagnosed FD, IBS, and/or overlap, who were observed by gastroenterologists from November 01, 2017, through March 30, 2018, who received the drug Kolofort in monotherapy for 12 weeks, 2 tablets twice a day. To assess the presence and severity of symptoms of functional gastrointestinal disorders (FGID), the "7*7" questionnaire developed by a working group from the Russian Gastroenterological Association was used. The evaluated parameters included the proportion of patients: who had a 50% or more reduction in the total score; who have switched to the less severe category of the condition; who have switched to the "healthy" or "borderline ill" severity categories; and the change in the score in domains 1-7. RESULTS The final efficacy analysis included data from 9254 patients. A decrease in the total score by 50% or more was observed in 80.45% of patients with FD, 79.02% of patients with IBS, and in 83% of patients with both IBS and FD. Switch to a lower severity category of the condition at the end of therapy was noted in 93.35% of patients with FD, in 93.80% of cases in patients with IBS, and in 96.17% of cases in patients with a combination of IBS and FD. A total of 94 adverse events (AEs) were reported in 80 patients (0.65%). CONCLUSION The COMFORT program has demonstrated the positive effect of treatment in the majority of patients with IBS and FD and their combination in real clinical practice.
Collapse
Affiliation(s)
- Vladimir T. Ivashkin
- I.M. Sechenov First Moscow State Medical University (Sechenov University), 8–2, Trubetskaya St, 119991 Moscow, Russian Federation
| | - Elena A. Poluektova
- I.M. Sechenov First Moscow State Medical University (Sechenov University), 8–2, Trubetskaya St, 119991 Moscow, Russian Federation
| | - Alexey B. Glazunov
- Department of Medical Information, Research and Production Company Materia Medica Holding LLC “NPF” MATERIA MEDICA HOLDING, 9, 3rd Samotyochny Per, Moscow, Russian Federation 127473
| | - Mikhail A. Putilovskiy
- Department of Medical Information, Research and Production Company Materia Medica Holding LLC “NPF” MATERIA MEDICA HOLDING, 9, 3rd Samotyochny Per, Moscow, Russian Federation 127473
| | - Oleg I. Epstein
- The Institute of General Pathology and Pathophysiology, 8, Baltiyskaya St, Moscow, Russian Federation 125315
| |
Collapse
|
|
3
|
Jin S, Zhang L, Wei YF, Zhang HJ, Wang CY, Zou H, Hu JM, Jiang JF, Pang LJ. Pure squamous cell carcinoma of the gallbladder locally invading the liver and abdominal cavity: A case report and review of the literature. World J Clin Cases 2019; 7:4163-4171. [PMID: 31832423 PMCID: PMC6906552 DOI: 10.12998/wjcc.v7.i23.4163] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Revised: 09/30/2019] [Accepted: 10/15/2019] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Gallbladder squamous cell carcinoma (GBSCC) is a rare subtype of malignancy and accounts for only 2%-3% of gallbladder malignancies. Due to its rapid development, most patients with GBSCC initially present with an advanced stage of the disease and hence a poor prognosis. The clinicopathological and biological features of SCC remain to be fully elucidated, owing to its uncommon occurrence. The majority of currently available data only described individual case reports or series analyses of trivial cases.
CASE SUMMARY A 64-year-old man was admitted for progressively poor abdominal distension and pain. Liver computed tomography (CT) showed infiltration of gallbladder carcinoma into the adjacent liver, and enlarged retroperitoneal lymph nodes. The patient underwent radical cholecystectomy. Part of the mass was grey and soft, and the neoplastic section showed a purulent-necrotic lesion. Hematoxylin and eosin staining revealed a moderately differentiated SCC. Immunohistochemical studies showed strong staining of the tumor for AE1/3 and CK5/6. Staining for CK19, CK7, and CAM5.2 was positive in the cytoplasm. Systemic chemotherapy was not administered because of the patient’s poor physical condition. After five months, CT and magnetic resonance cholangiopancreatography showed multiple metastases in the liver and abdominal cavity.
CONCLUSION Squamous components of GBSCC may explain the complex biological behavior, and CD109 may be involved in the pathogenesis.
Collapse
Affiliation(s)
- Shan Jin
- Department of Pathology, the First Affiliated Hospital to Shihezi University School of Medicine and Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
- Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
| | - Lu Zhang
- Department of Pathology, the First Affiliated Hospital to Shihezi University School of Medicine and Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
- Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
| | - Yuan-Feng Wei
- Department of Pathology, the First Affiliated Hospital to Shihezi University School of Medicine and Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
- Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
| | - Hai-Jun Zhang
- Department of Pathology, the First Affiliated Hospital to Shihezi University School of Medicine and Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
- Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
| | - Cheng-Yan Wang
- Department of Pathology, the First Affiliated Hospital to Shihezi University School of Medicine and Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
- Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
| | - Hong Zou
- Department of Pathology, the First Affiliated Hospital to Shihezi University School of Medicine and Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
- Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
| | - Jian-Ming Hu
- Department of Pathology, the First Affiliated Hospital to Shihezi University School of Medicine and Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
- Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
| | - Jin-Fang Jiang
- Department of Pathology, the First Affiliated Hospital to Shihezi University School of Medicine and Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
- Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
| | - Li-Juan Pang
- Department of Pathology, the First Affiliated Hospital to Shihezi University School of Medicine and Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
- Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi 832002, Xinjiang Uygur Autonomous Region, China
| |
Collapse
|